
Talus Bio
Talus Bio is a YC Summer 2021 (S21) company. Based in Seattle, WA, USA. Team of 16.
About Talus Bio
Summary
Talus Bio builds a structure-free drug discovery platform targeting genome regulators that have resisted conventional drug development. Its core tools are Ptarmigan-1, a model that predicts binding between proteins and small molecules using sequence alone, without requiring a 3D structure or known binding pocket, and MARMOT, a functional proteomics technology that measures proteins in live human cells rather than artificial systems. Together they let drug hunters screen billions of compounds against disordered and flexible targets and measure compound effects across the entire regulome in a single experiment.
Go-to-market
Customers in pharmaceutical drug discovery access Ptarmigan-1 directly through the Talus Bio platform.
From the Y Combinator listing
Discovering drugs that target the DNA regulome
We have built a platform that enables drug discovery and development for previously undruggable genome regulators ("the regulome"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Seattle, WA, USA
- 16
- Active
- Early
Founders (2)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works